Home Transmembrane Transporters ATPase

ATPase Inhibitors/Activators

Other Transmembrane Transporters Related Inhibitors

CFTR CRM1 Calcium Channel Proton Pump P-gp Sodium Channel Potassium Channel CD markers GLUT Amino acid transporter

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S7099 (-)-Blebbistatin (-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.
Molecular Cancer Research, November 01, 2023, 1205-1219
Cyborg and Bionic Systems, March 24, 2026, 0552
Molecular Biology of the Cell, March 01, 2021, 413-421
Verified customer review of (-)-Blebbistatin
S7895 Thapsigargin Thapsigargin is a potent, non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) with IC50 of 0.353 nM or 0.448 nM for the carbachol-evoked [Ca2+]i-transients with or without a KCl-prestimulation. Thapsigargin induces cell apoptosis. Thapsigargin is extracted from a plant, Thapsia garganica.
International Journal of Biological Sciences, 2026, 733
Nature Communications, 2025, 11092
The EMBO Journal, 2025, 1107-1130
S1413 Bafilomycin A1 (Baf-A1) Bafilomycin A1 (Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM, and it is found to inhibit autophagy while inducing apoptosis.
Cell & Bioscience, July 05, 2025, 96
Journal of Cellular and Molecular Medicine, February 28, 2021, 3348-3360
Cells, August 09, 2025, 1231
Verified customer review of Bafilomycin A1 (Baf-A1)
S2623 Omecamtiv mecarbil (CK-1827452) Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure, currently in Phase 2.
Nat Biotechnol, 2025, 10.1038/s41587-025-02725-6
Eur Heart J, 2025, ehaf813
Journal of General Physiology, 2025, e202513762
Verified customer review of Omecamtiv mecarbil (CK-1827452)
S1238 Tamoxifen Tamoxifen is an orally active, selective estrogen receptor modulator (SERM) which exhibits both estrogenic agonist and antagonist effects. It blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity.
Cell Discov, 2025, 11(1):89
Nat Genet, 2025, 57(9):2192-2202
Cell Metab, 2025, 37(8):1715-1731.e11
Verified customer review of Tamoxifen
S1478 Oligomycin A (MCH 32) Oligomycin A (MCH 32), a dominant analog of the isomers, is an inhibitor of mitochondrial F1FO ATP synthase which inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria. It inhibits ATP synthase by blocking its proton channel (Fo subunit), which is necessary for oxidative phosphorylation of ADP to ATP. It also induces apoptosis in a variety of cell types.
Nat Commun, 2025, 16(1):212
Int J Biol Sci, 2025, 21(1):233-250
Cell Rep, 2025, 44(7):115973
Verified customer review of Oligomycin A (MCH 32)
S7046 Brefeldin A (BFA chemical) Brefeldin A (BFA) is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Protein Cell, 2025, pwaf020
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
J Integr Plant Biol, 2025, 67(8):2229-2244
Verified customer review of Brefeldin A (BFA chemical)
S8101 CB-5083 CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor with IC50 of 11 nM. Phase 1.
Nat Commun, 2025, 16(1):3546
EMBO J, 2025, 10.1038/s44318-025-00517-x
Proc Natl Acad Sci U S A, 2025, 122(27):e2426218122
Verified customer review of CB-5083
S4290 Digoxin Digoxin is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
J Exp Clin Cancer Res, 2025, 44(1):294
Pharmaceuticals (Basel), 2025, 18(2)181
Drug Metab Dispos, 2025, 53(4):100049
S7266 Golgicide A Golgicide A is a potent and rapidly reversible GBF1 inhibitor.
Stem Cell Research & Therapy, March 7, 2025, 121
Stem Cell Research & Therapy, March 07, 2025, 121
Journal of Biological Chemistry, February 10, 2017, 2315-2327
Verified customer review of Golgicide A

Signaling Pathway Map